MX2020002769A - Composiciones de polvo seco con estearato de magnesio. - Google Patents
Composiciones de polvo seco con estearato de magnesio.Info
- Publication number
- MX2020002769A MX2020002769A MX2020002769A MX2020002769A MX2020002769A MX 2020002769 A MX2020002769 A MX 2020002769A MX 2020002769 A MX2020002769 A MX 2020002769A MX 2020002769 A MX2020002769 A MX 2020002769A MX 2020002769 A MX2020002769 A MX 2020002769A
- Authority
- MX
- Mexico
- Prior art keywords
- dry powder
- magnesium stearate
- powder compositions
- âμm
- powder composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0033—Details of the piercing or cutting means
- A61M15/0035—Piercing means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0033—Details of the piercing or cutting means
- A61M15/0041—Details of the piercing or cutting means with movable piercing or cutting means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A61M11/003—Particle size control by passing the aerosol trough sieves or filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
- A61M15/0023—Mouthpieces therefor retractable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/582—Means for facilitating use, e.g. by people with impaired vision by tactile feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una composición de polvo seco estable para inhalación incluye ácido acetilsalicílico en partículas que tienen un diámetro aerodinámico medio de masa (MMAD) en un intervalo de aproximadamente 1 µm a aproximadamente 5 µm. La composición de polvo seco puede contener un excipiente farmacéuticamente aceptable, tal como un estearato, en una cantidad que varía de aproximadamente 0.04% (p/p) a aproximadamente 0.06% (p/p), o de aproximadamente 0.4% (p/p) a aproximadamente 0.6% (p/p) de la composición.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762562295P | 2017-09-22 | 2017-09-22 | |
PCT/US2017/053569 WO2019059953A2 (en) | 2017-09-22 | 2017-09-26 | DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020002769A true MX2020002769A (es) | 2020-07-20 |
Family
ID=65200304
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020002769A MX2020002769A (es) | 2017-09-22 | 2017-09-26 | Composiciones de polvo seco con estearato de magnesio. |
MX2023006856A MX2023006856A (es) | 2017-09-22 | 2020-03-12 | Composiciones de polvo seco con estearato de magnesio. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023006856A MX2023006856A (es) | 2017-09-22 | 2020-03-12 | Composiciones de polvo seco con estearato de magnesio. |
Country Status (9)
Country | Link |
---|---|
US (3) | US10195147B1 (es) |
EP (1) | EP3684338A4 (es) |
JP (2) | JP7493449B2 (es) |
KR (1) | KR102507987B1 (es) |
CN (2) | CN115919780A (es) |
AU (1) | AU2017432640B2 (es) |
CA (1) | CA3076353A1 (es) |
MX (2) | MX2020002769A (es) |
WO (1) | WO2019059953A2 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016518388A (ja) * | 2013-04-30 | 2016-06-23 | オティトピック インク. | 乾燥粉末配合および使用方法 |
CA3001962C (en) * | 2015-12-22 | 2022-09-13 | Ventaleon Gmbh | Treatment of moderate to severe influenza |
EP3463378A4 (en) * | 2016-06-03 | 2020-01-08 | Otitopic Inc. | DRY POWDER FORMULAS FOR INHALATION |
CA3064012A1 (en) | 2017-05-30 | 2018-12-06 | Rhoshan Pharmaceuticals, Inc. | In-vial deposition of a stable, sterile and crystalline o-acetyl salicylic acid (aspirin) |
KR102507987B1 (ko) * | 2017-09-22 | 2023-03-21 | 벡추라 인코포레이티드 | 스테아르산마그네슘을 갖는 건조 분말 조성물 |
WO2023205388A1 (en) * | 2022-04-22 | 2023-10-26 | Board Of Regents, The University Of Texas System | Inhaled antibacterial formulations for treating lung infections |
Family Cites Families (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
FR2580634B1 (fr) | 1985-04-19 | 1988-08-05 | Rhone Poulenc Sante | Nouveau derive de l'acide acetylsalicylique, sa preparation et les compositions pharmaceutiques qui le contiennent |
DE3814856A1 (de) | 1988-05-02 | 1989-11-16 | Verla Pharm | Mittel zur prophylaxe des herzinfarkts und zur verhuetung des reinfarkts |
IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
US5327883A (en) | 1991-05-20 | 1994-07-12 | Dura Pharmaceuticals, Inc. | Apparatus for aerosolizing powdered medicine and process and using |
US20070116761A1 (en) | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US5533502A (en) | 1993-05-28 | 1996-07-09 | Vortran Medical Technology, Inc. | Powder inhaler with aerosolization occurring within each individual powder receptacle |
US5875776A (en) | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
MXPA01004828A (es) | 1998-11-12 | 2002-09-18 | Frank G Pilkiewicz | Sistema de inhalacion. |
US20030176421A1 (en) | 1999-12-30 | 2003-09-18 | Watson John W. | Prokinetic agents for treating gastric hypomotility and related disorders |
ATE392885T1 (de) | 2000-02-28 | 2008-05-15 | Pharmakodex Ltd | Verabreichungssystemen für oral anzuwendende arzneimittel |
PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
GB0010709D0 (en) | 2000-05-03 | 2000-06-28 | Vectura Ltd | Powders for use a in dry powder inhaler |
EP1177805A1 (en) | 2000-07-31 | 2002-02-06 | Maryland Financial Inc. | Powder inhaler |
US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
WO2002051389A2 (en) | 2000-12-22 | 2002-07-04 | Aspen Aerogels, Inc. | Aerogel powder comprising therapeutic agents |
EP1238680B1 (en) | 2001-03-05 | 2003-12-10 | Ivo Pera | Inhaling device for dispersing powdered medicaments contained in a capsule through the respiratory tract |
US20060293217A1 (en) | 2001-03-19 | 2006-12-28 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained release |
US20040049022A1 (en) | 2001-04-24 | 2004-03-11 | Nyce Jonathan W. | Composition & methods for treatment and screening |
GB0129270D0 (en) | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Pharmaceutical combination |
GB0129397D0 (en) | 2001-12-07 | 2002-01-30 | Pfizer Ltd | Pharmaceutical combination |
AU2003215334A1 (en) | 2002-02-22 | 2003-09-09 | Advanced Inhalation Research, Inc. | Inhalable formulations for sustained release |
US7405207B2 (en) | 2002-06-17 | 2008-07-29 | Epigenesis Pharmaceuticals, Inc. | Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof |
AU2003276131A1 (en) | 2002-06-18 | 2003-12-31 | Epigenesis Pharmaceuticals, Inc. | A dry powder oligonucleotide formulation, preparation and its uses |
WO2004030659A1 (en) | 2002-09-30 | 2004-04-15 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
GB0226105D0 (en) | 2002-11-08 | 2002-12-18 | St Georges S Entpr Ltd | Pain relief agents |
US7516741B2 (en) | 2002-12-06 | 2009-04-14 | Novartis Ag | Aerosolization apparatus with feedback mechanism |
SE0203687D0 (sv) | 2002-12-13 | 2002-12-13 | Ian Harwigsson Med Adagit Fa | Pharmaceutical Porous Particles |
DK1610850T3 (da) * | 2003-04-09 | 2012-06-25 | Novartis Ag | Aerosolapparat med luftindløbsskærm |
WO2004091633A1 (en) | 2003-04-09 | 2004-10-28 | Wyeth | Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.o]non-1 (7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof |
GB0312419D0 (en) | 2003-05-30 | 2003-07-02 | Boots Healthcare Int Ltd | Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess |
SE527069C2 (sv) | 2003-06-19 | 2005-12-13 | Mederio Ag | Förfarande och anordning för administrering av läkemedelspulver |
US7041286B2 (en) | 2003-07-23 | 2006-05-09 | Nerenberg Arnold P | Composition for mitigating a pernicious thrombotic event |
JP2007502815A (ja) | 2003-08-20 | 2007-02-15 | イーライ リリー アンド カンパニー | Ppar調節因子 |
EP1658060A2 (en) | 2003-08-22 | 2006-05-24 | Boehringer Ingelheim Pharmaceuticals Inc. | Methods of treating copd and pulmonary hypertension |
WO2005039489A2 (en) | 2003-09-24 | 2005-05-06 | Polymerix Corporation | Compositions and methods for the inhibition of bone growth and resorption |
JP2011168615A (ja) * | 2003-10-16 | 2011-09-01 | Daiichi Sankyo Healthcare Co Ltd | サリチル酸類含有経口組成物 |
WO2005040163A1 (en) | 2003-10-28 | 2005-05-06 | Dr. Reddy's Laboratories Ltd | Heterocyclic compounds that block the effects of advanced glycation end products (age) |
WO2005041886A2 (en) | 2003-10-31 | 2005-05-12 | Metaphore Pharmaceuticals, Inc. | Methods for generating or increasing revenues related to pain inhibitor commerce |
WO2005079234A2 (en) | 2004-02-05 | 2005-09-01 | Etienne-Emile Baulieu | Treatment of pulmonary artery hypertension with dhea, dheas, dhea analogs or dhea derivatives |
US20050187268A1 (en) | 2004-02-23 | 2005-08-25 | Prolexys Pharmaceuticals Inc. | Non-peptidyl agents with pHSP20-like activity, and uses thereof |
KR20070006891A (ko) | 2004-05-04 | 2007-01-11 | 화이자 인코포레이티드 | 치환된 메틸 아릴 또는 헤테로아릴 아미드 화합물 |
US7189750B2 (en) | 2004-05-05 | 2007-03-13 | Renopharm Ltd. | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof |
AU2005247369A1 (en) | 2004-05-10 | 2005-12-08 | Mdrna, Inc. | Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
WO2006017354A1 (en) | 2004-07-13 | 2006-02-16 | Pharmacofore, Inc. | Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing disease or pain |
WO2006017505A2 (en) | 2004-08-04 | 2006-02-16 | Schering Corporation | Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases |
JP4948418B2 (ja) | 2004-11-02 | 2012-06-06 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | Nkt細胞を抑制するための方法 |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
GB0426301D0 (en) * | 2004-11-30 | 2004-12-29 | Vectura Ltd | Pharmaceutical formulations |
EA200800041A1 (ru) * | 2005-06-13 | 2008-04-28 | Элан Фарма Интернэшнл Лтд. | Составы с наночастицами клопидогреля, содержащие комбинацию клопидогреля и аспирина |
TWI366460B (en) | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
EP1919939A2 (en) | 2005-07-27 | 2008-05-14 | Nastech Pharmaceutical Company Inc. | Tight junction modulating peptide components for enhancing mucosal delivery |
WO2008051186A2 (en) | 2005-08-09 | 2008-05-02 | Nanobio Corporation | Nanoemulsion containing compositions having ant i -inflammatory activity |
ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
EP1973523A2 (en) | 2005-12-15 | 2008-10-01 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration |
JP2009519975A (ja) | 2005-12-16 | 2009-05-21 | ユニバーシティ・オブ・カンザス | 治療薬を送達するナノクラスター |
WO2007072503A2 (en) | 2005-12-21 | 2007-06-28 | Panacea Biotec Ltd. | Combinations for managing inflammation and associated disorders |
WO2007114881A1 (en) | 2006-01-24 | 2007-10-11 | Nexbio, Inc. | Technology for preparation of macromolecular microspheres |
GB0605723D0 (en) | 2006-03-23 | 2006-05-03 | 3M Innovative Properties Co | Powder filling processes |
HUE048024T2 (hu) | 2006-08-10 | 2020-05-28 | Roy C Levitt | Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra |
GB0617171D0 (en) | 2006-08-31 | 2006-10-11 | Generics Uk Ltd | Novel compositions and methods |
US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
GB0621957D0 (en) | 2006-11-03 | 2006-12-13 | Vectura Group Plc | Inhaler devices and bespoke pharmaceutical compositions |
GB0700839D0 (en) | 2007-01-17 | 2007-02-21 | Braithwaite Philip | Device |
EP1964564A1 (en) | 2007-04-19 | 2008-09-03 | LAB International SRL | Breakthrough Pain Management |
US8530463B2 (en) | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
CA2687720A1 (en) | 2007-06-13 | 2008-12-24 | Amgen Inc. | Il-17 heteromeric receptor complex |
WO2009011782A2 (en) | 2007-07-13 | 2009-01-22 | Abbott Biotechnology Ltd. | METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR |
US20090098207A1 (en) | 2007-07-24 | 2009-04-16 | Nexbio, Inc. | Technology for the Preparation of Microparticles |
WO2009019598A2 (en) * | 2007-08-03 | 2009-02-12 | Dr. Reddy's Laboratories Ltd. | Inhalation therapy for respiratory disorders |
US8614255B2 (en) | 2007-08-21 | 2013-12-24 | Civitas Therapeutics, Inc. | Pulmonary pharmaceutical formulations |
US9358242B2 (en) | 2007-08-30 | 2016-06-07 | Prelief Inc. | Calcium glycerophosphate for treating and preventing respiratory diseases or conditions |
JP5767812B2 (ja) | 2007-12-06 | 2015-08-19 | バーグ リミテッド ライアビリティ カンパニー | 生物学的利用率が向上した吸入可能な組成物 |
CA2710349A1 (en) | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide -donating compounds and uses thereof |
DE102008004386A1 (de) | 2008-01-14 | 2009-07-23 | Activaero Gmbh | Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen |
RU2534527C2 (ru) | 2008-01-15 | 2014-11-27 | Юниверсите Де Страсбур | Синтез лактонов резорциловой кислоты, используемых в качестве терапевтических агентов |
JP2011514335A (ja) | 2008-02-21 | 2011-05-06 | アムジェン インコーポレイテッド | Il−17ra−il−17rbアンタゴニストおよび該アンタゴニストの使用 |
EP2255797A4 (en) | 2008-02-22 | 2011-09-07 | Hanall Biopharma Co Ltd | COMPOSITE PREPARATION |
GB0803369D0 (en) | 2008-02-25 | 2008-04-02 | Helperby Therapeutics Ltd | Biological materials and uses thereof |
JP2011516485A (ja) | 2008-04-04 | 2011-05-26 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Itpkb阻害剤としての化合物および組成物 |
WO2009128933A1 (en) | 2008-04-15 | 2009-10-22 | Sarcode Corporation | Aerosolized lfa-1 antagonists for use in localized treatment of immune related disorders |
US8507488B2 (en) | 2008-05-13 | 2013-08-13 | Irm Llc | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
US20110112134A1 (en) | 2008-05-16 | 2011-05-12 | Amira Pharmaceuticals, Inc. | Tricyclic Antagonists of Prostaglandin D2 Receptors |
AU2009271162A1 (en) | 2008-07-15 | 2010-01-21 | Merck Sharp & Dohme Corp. | Intranasal compositions comprising a decongestant and a corticosteroid |
BRPI0915783A2 (pt) | 2008-07-18 | 2018-05-22 | Prosonix Ltd | processo para aumentar a cristalinidade de pelo menos um material sólido, partícula, composição farmacêutica ou agroquímica , e, inalador |
WO2010011329A2 (en) | 2008-07-23 | 2010-01-28 | Map Pharmaceuticals, Inc. | The delivery of powdered drug via inhalation |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
CA2734381A1 (en) | 2008-09-12 | 2010-03-18 | Critical Pharmaceuticals Limited | Improvements in the absorption of therapeutic agents across mucosal membranes or the skin |
CA2755543A1 (en) | 2009-03-13 | 2010-09-16 | Nucitec S.A. De C.V. | Compositions and methods for treatment and prevention of cardiovascular disease |
WO2010117951A1 (en) | 2009-04-06 | 2010-10-14 | The Regents Of The University Of California | Inhibitors of soluble epoxide hydrolase to inhibit or prevent niacin-induced flushing |
ES2552805T3 (es) | 2009-04-20 | 2015-12-02 | Auspex Pharmaceuticals, Llc | Inhibidores piperidínicos de la cinasa Janus 3 |
EP2429495A4 (en) | 2009-05-15 | 2014-01-22 | Shin Nippon Biomedical Lab Ltd | INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PHARMACOKINETICS |
JP5720009B2 (ja) | 2009-05-18 | 2015-05-20 | アダミス ファーマシューティカルズ コーポレーション | ドライパウダー吸入器 |
ES2662769T3 (es) | 2009-05-18 | 2018-04-09 | Adamis Pharmaceuticals Corporation | Contadores de dosis de inhalador de polvo seco |
JP2012528844A (ja) | 2009-06-01 | 2012-11-15 | バイオコピア リミテッド | 好中球によって引き起こされる疾患の治療におけるアンレキサノクスの使用 |
GB201111485D0 (en) | 2011-07-05 | 2011-08-17 | Biocopea Ltd | Drug composition and its use in therapy |
GB0917054D0 (en) | 2009-09-29 | 2009-11-11 | Cytoguide As | Agents, uses and methods |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
GB0918431D0 (en) | 2009-10-21 | 2009-12-09 | Prosonix Ltd | Process for improving crystallinity |
GB0921481D0 (en) | 2009-12-08 | 2010-01-20 | Vectura Ltd | Process and product |
SG184473A1 (en) | 2010-04-07 | 2012-11-29 | Abbvie Inc | Tnf-alpha binding proteins |
JP5877201B2 (ja) | 2010-08-30 | 2016-03-02 | パルマトリックス,インコーポレイテッド | 肺疾患を治療するための乾燥粉末製剤および方法 |
US8883844B2 (en) | 2010-09-24 | 2014-11-11 | Nitrogenix Inc. | Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions |
WO2012078804A1 (en) | 2010-12-07 | 2012-06-14 | Respira Therapeutics, Inc. | Dry powder inhaler |
CN102058886A (zh) | 2010-12-20 | 2011-05-18 | 云南白药集团无锡药业有限公司 | 医用粉雾剂及其应用 |
WO2012107364A1 (en) | 2011-02-07 | 2012-08-16 | Scipharm Sàrl | Novel composition for the treatment of cystic fibrosis |
GB201102237D0 (en) | 2011-02-09 | 2011-03-23 | Kuecept Ltd | Particle formulation |
JP6031510B2 (ja) | 2011-04-12 | 2016-11-24 | モイライ マトリックス インコーポレイテッド | 異常な線維芽細胞増殖及び細胞外マトリックスの沈着を特徴とする疾患、症状又はプロセスを予防又は治療する組成物及び方法 |
US20120306613A1 (en) | 2011-06-02 | 2012-12-06 | Nokia Siemens Networks Oy | Sensor allocation |
US20140239525A1 (en) | 2011-06-17 | 2014-08-28 | Board Of Regents, University Of Texas System | Inhalable pharmaceutical compositions |
US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
EA201490538A1 (ru) | 2011-09-06 | 2014-08-29 | Верона Фарма Плк | Лечение кашля и его приступов |
CA2858997C (en) | 2011-12-16 | 2020-03-31 | Indosys Limited | Medicament unit dose cartridge and delivery device |
CN104203985A (zh) | 2012-01-31 | 2014-12-10 | 天蓝制药公司 | 用于治疗性递送的环糊精类聚合物 |
CN104703584B (zh) * | 2012-02-28 | 2019-05-31 | 艾塞尤提卡控股公司 | 可吸入药物组合物 |
CN107596518B (zh) | 2012-02-29 | 2021-04-23 | 普马特里克斯营业公司 | 可吸入干粉剂 |
CA2868277A1 (en) | 2012-03-26 | 2013-10-03 | Rolf E. Swenson | Novel sphingosine 1-phosphate receptor antagonists |
GB201205632D0 (en) | 2012-03-30 | 2012-05-16 | Vectura Ltd | Method and apparatus |
NZ741873A (en) | 2012-05-03 | 2019-04-26 | Kala Pharmaceuticals Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
WO2013176622A1 (en) | 2012-05-21 | 2013-11-28 | Agency For Science, Technology And Research (A*Star) | A dry powder formulation |
ES2658972T3 (es) | 2012-06-20 | 2018-03-13 | University Of Waterloo | Sistema de administración de nanopartículas mucoadhesivas |
WO2014048065A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
WO2014053482A1 (en) | 2012-10-03 | 2014-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza with invariant nkt cell agonists |
WO2014074422A1 (en) | 2012-11-07 | 2014-05-15 | Merck Sharp & Dohme Corp. | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
EP2948148B1 (en) | 2013-01-28 | 2020-07-29 | Incozen Therapeutics Pvt. Ltd. | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide |
TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
GB201305813D0 (en) | 2013-03-28 | 2013-05-15 | Vectura Ltd | Compositions and methods |
JP2016518388A (ja) | 2013-04-30 | 2016-06-23 | オティトピック インク. | 乾燥粉末配合および使用方法 |
CA2913235C (en) | 2013-05-23 | 2021-07-13 | Aztherapies, Inc. | Methods for delivering cromolyn |
TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽 |
WO2015054574A1 (en) | 2013-10-11 | 2015-04-16 | Zisman Lawrence S | Spray dry formulations |
DK3087980T3 (en) | 2013-12-23 | 2019-02-18 | Xiaoguang Wen | DOUBLE LAYER TABLE AND METHOD OF PRODUCING THEREOF |
SG11201606842RA (en) | 2014-02-20 | 2016-09-29 | Allergan Inc | Complement component c5 antibodies |
EP3107548B8 (en) | 2014-02-20 | 2022-07-20 | Otitopic Inc. | Dry powder formulations for inhalation |
JP6643244B2 (ja) | 2014-02-27 | 2020-02-12 | アラーガン、インコーポレイテッドAllergan,Incorporated | 補体因子Bb抗体 |
CN106715443A (zh) | 2014-03-26 | 2017-05-24 | 坎格特生物技术制药有限责任公司 | Fl118母核化学结构平台产生用于治疗人类疾病的fl118衍生物的用途 |
WO2015153838A1 (en) | 2014-04-02 | 2015-10-08 | Rogne Bioscience Inc. | Methods and compositions for treating inflammatory disorders |
EP3129013A1 (en) | 2014-04-10 | 2017-02-15 | Crowley, Patrick | Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders |
WO2016019253A1 (en) * | 2014-07-31 | 2016-02-04 | Otitopic Inc. | Dry powder formulations for inhalation |
CN105749386B (zh) * | 2015-03-21 | 2018-11-09 | 深圳百美酶生物医药科技有限公司 | 手动干粉吸入器 |
CN106619549B (zh) * | 2017-01-03 | 2019-12-06 | 江苏吴中医药集团有限公司苏州制药厂 | 一种替格瑞洛与阿司匹林复合片剂及其制备方法 |
KR102507987B1 (ko) * | 2017-09-22 | 2023-03-21 | 벡추라 인코포레이티드 | 스테아르산마그네슘을 갖는 건조 분말 조성물 |
-
2017
- 2017-09-26 KR KR1020207011576A patent/KR102507987B1/ko active Application Filing
- 2017-09-26 CA CA3076353A patent/CA3076353A1/en active Pending
- 2017-09-26 JP JP2020516655A patent/JP7493449B2/ja active Active
- 2017-09-26 US US15/716,492 patent/US10195147B1/en active Active
- 2017-09-26 CN CN202211135205.1A patent/CN115919780A/zh active Pending
- 2017-09-26 WO PCT/US2017/053569 patent/WO2019059953A2/en unknown
- 2017-09-26 AU AU2017432640A patent/AU2017432640B2/en active Active
- 2017-09-26 EP EP17925874.4A patent/EP3684338A4/en active Pending
- 2017-09-26 CN CN201780095045.3A patent/CN111315363B/zh active Active
- 2017-09-26 MX MX2020002769A patent/MX2020002769A/es unknown
-
2019
- 2019-02-02 US US16/266,042 patent/US11077058B2/en active Active
-
2020
- 2020-03-12 MX MX2023006856A patent/MX2023006856A/es unknown
-
2021
- 2021-08-01 US US17/391,021 patent/US20220016030A1/en active Pending
-
2022
- 2022-06-20 JP JP2022098813A patent/JP2022137070A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2017432640A1 (en) | 2020-03-19 |
KR20200090755A (ko) | 2020-07-29 |
CN111315363A (zh) | 2020-06-19 |
JP7493449B2 (ja) | 2024-05-31 |
JP2022137070A (ja) | 2022-09-21 |
CN115919780A (zh) | 2023-04-07 |
EP3684338A4 (en) | 2021-06-23 |
US10195147B1 (en) | 2019-02-05 |
CN111315363B (zh) | 2022-10-11 |
KR102507987B1 (ko) | 2023-03-21 |
JP2021502954A (ja) | 2021-02-04 |
CA3076353A1 (en) | 2019-03-28 |
US11077058B2 (en) | 2021-08-03 |
US20190336448A1 (en) | 2019-11-07 |
KR20230040375A (ko) | 2023-03-22 |
MX2023006856A (es) | 2023-06-22 |
US20220016030A1 (en) | 2022-01-20 |
EP3684338A2 (en) | 2020-07-29 |
WO2019059953A2 (en) | 2019-03-28 |
AU2017432640B2 (en) | 2023-11-30 |
WO2019059953A3 (en) | 2019-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023006856A (es) | Composiciones de polvo seco con estearato de magnesio. | |
PH12017502326B1 (en) | Orodispersible dosage unit containing an estetrol component | |
EP4311541A3 (en) | Cryoprotective agents for particulate formulations | |
NZ723838A (en) | Cannabinoid compositions and uses | |
PH12017502325A1 (en) | Orodispersible dosage unit containing an estetrol component | |
BR112013026363A2 (pt) | nanossuspensões de fármaco criodessecadas | |
MY175781A (en) | Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation | |
MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
WO2020127819A3 (en) | Pharmaceutical composition comprising apixaban | |
MY191712A (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
IN2013MU01177A (es) | ||
MX2018014790A (es) | Formulacion combinada de tres compuestos antivirales. | |
WO2017064652A3 (en) | Low dose oral dipyridamole compositions and uses thereof | |
WO2016197042A8 (en) | Modified or targeted release formulations of linaclotide | |
MX2023003229A (es) | Composicion para mejorar la absorcion de suplementos. | |
WO2020055357A3 (en) | Inhalation compositions comprising phosphodiesterase-4 inhibitor | |
WO2019104062A8 (en) | Polymorphs and uses thereof | |
WO2020013793A3 (en) | Inhalation compositions comprising dopamine agonists | |
MX2020010928A (es) | Una composicion farmaceutica en polvo seco para inhalacion que comprende una hormona tiroidea. | |
MX2022002681A (es) | Composicion farmaceutica. | |
MX2019011701A (es) | Composiciones de canabinoide y usos. | |
WO2019125166A3 (en) | Hyaluronic acid formulations | |
PH12019500473A1 (en) | Solid composition for quick ingestion with facilitated swallowing, in the form of solid, non-agglomerated particles, comprising two different types of particles | |
MX2018013274A (es) | Uso de alcoholes de azucar en composiciones de tibolona. | |
PH12018550075A1 (en) | An oral osmotic pharmaceutical composition of vildagliptin |